Artivion, Inc. (AORT)
| Market Cap | 733.95M |
| Revenue (ttm) | 339.73M |
| Net Income (ttm) | -24.55M |
| Shares Out | 41.05M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | 357.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 167,928 |
| Open | 18.25 |
| Previous Close | 18.22 |
| Day's Range | 17.78 - 18.25 |
| 52-Week Range | 11.44 - 19.00 |
| Beta | 1.54 |
| Analysts | Buy |
| Price Target | 18.50 (+3.47%) |
| Earnings Date | Feb 15, 2024 |
About AORT
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatmen... [Read more]
Financial Performance
In 2022, Artivion's revenue was $313.79 million, an increase of 5.00% compared to the previous year's $298.84 million. Losses were -$19.19 million, 29.4% more than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for AORT stock is "Buy." The 12-month stock price forecast is $18.5, which is an increase of 3.47% from the latest price.
News
Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D.
Reaffirms Financial Guidance Provided on November 2, 2023 ATLANTA , Dec. 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease t...
Artivion Announces Completion of Enrollment in PERSEVERE Trial
ATLANTA , Nov. 9, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed enrollment in the PE...
Artivion to Participate in Upcoming Investor Conferences
ATLANTA , Nov. 8, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming i...
Artivion Reports Third Quarter 2023 Financial Results
Third Quarter and Recent Business Highlights: Achieved revenue of $87.9 million in the third quarter of 2023 versus $76.8 million in the third quarter of 2022, an increase of 14% on a GAAP basis and 1...
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2023 Financial Results
ATLANTA , Oct. 19, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2023 financial results...
Artivion Announces Presentation of Real World Data from Post Market Study of On-X® Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin
Late-Breaking Science Presented at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting ATLANTA , Oct. 5, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and va...
Artivion Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting
Interim Data Demonstrate Meaningful Reduction of All-Cause Mortality with AMDS ATLANTA , Oct. 5, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focuse...
Artivion to Present at the Deutsche Bank 31st Annual Leveraged Finance Conference
ATLANTA, Sept. 26, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deut...
Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase
ATLANTA , Sept. 14, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually at the up...
Artivion Reports Second Quarter 2023 Financial Results
Second Quarter and Recent Business Highlights: Achieved revenue of $89.3 million in the second quarter of 2023 versus $80.3 million in the second quarter of 2022, an increase of 11% on both a GAAP and...
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2023 Financial Results
ATLANTA , July 20, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2023 financial result...
Artivion Announces FDA PMA Approval of PerClot and Transfer of PMA to Baxter
Artivion to Receive $18.75 Million Milestone Payment Under Previously Announced Agreement Artivion to Begin Supplying Product to Baxter Under Transitional Manufacturing and Supply Agreement ATLANTA , ...
Artivion Reports First Quarter 2023 Financial Results
First Quarter and Recent Business Highlights: Achieved revenue of $83.2 million in the first quarter of 2023 versus $77.2 million in the first quarter of 2022, an increase of 8% on a GAAP basis and an...
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2023 Financial Results
ATLANTA , April 20, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2023 financial result...
Artivion to Participate in the 22nd Annual Needham Virtual Healthcare Conference
ATLANTA , April 10, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at th...
Artivion to Participate in the Oppenheimer 33rd Annual Healthcare Conference
ATLANTA , March 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the...
Artivion Reports Fourth Quarter and Full Year 2022 Financial Results
Fourth Quarter and Recent Business Highlights: Achieved revenue of $79.4 million in the fourth quarter of 2022 versus $79.4 million in the fourth quarter of 2021, flat on a GAAP basis and an increase ...
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2022 Financial Results
ATLANTA , Feb. 2, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2022 fin...
Artivion Reports Third Quarter 2022 Financial Results
Third Quarter and Recent Business Highlights: Achieved revenue of $76.8 million in the third quarter of 2022 versus $72.2 million in the third quarter of 2021, an increase of 6% on a GAAP basis and 11...
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2022 Financial Results
ATLANTA , Oct. 20, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2022 financial results...
Elizabeth Hoff Joins Artivion Board of Directors
ATLANTA , Sept. 29, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Elizabeth A.
Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial
Study Was Evaluating the Use of Apixaban in Patients Treated with Mechanical Aortic Valves ATLANTA, Sept. 23, 2022 /PRNewswire/ --- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery ...
Artivion to Present at the Deutsche Bank 30th Annual Leveraged Finance Conference
ATLANTA , Sept. 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deu...
Artivion Reports Second Quarter 2022 Financial Results
ATLANTA , Aug. 4, 2022 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Achieved revenue of $80.3 million in the second quarter 2022 versus $76.1 million in the second quarter of 2021, ...
Artivion Initiates Enrollment in PERSEVERE Clinical Trial
Study Designed to Evaluate the Safety and Efficacy of the AMDS Hybrid Prosthesis to Treat Acute DeBakey Type I Aortic Dissections & Support U.S. FDA PMA Submission ATLANTA , July 27, 2022 /PRNewswire/...